Jul 27, 2021
The company is prepared to meet the record levels of demand seen during the 2020/21 influenza season amidst the ongoing COVID-19 pandemic. Summit, NJ, USA 27 Jul 2021 Seqirus offers a...
Jun 1, 2021Seqirus strengthens U.K. influenza vaccine response as high-speed fill and finish facility begins rolling 30 million doses in Liverpool
First doses of Seqirus’s enhanced influenza vaccine, destined for the U.K., come off a new high-speed fill-and-finish line in Liverpool. Liverpool, UK 01 Jun 2021 Seqirus Liverpool is the...
Dec 14, 2020Seqirus Presents Real-World Data for Cell-Based Quadrivalent Seasonal Influenza Vaccine (QIVc) at ESWI 2020
This news release is intended for Health Professional media only. Maidenhead, UK 14 Dec 2020 Seqirus, a global leader in influenza prevention, today presented new real-world evidence (RWE) at the...
Dec 14, 2020Seqirus Presents New Late-Breaking Data at ESWI 2020 Highlighting Value of MF59®-Adjuvanted Seasonal Influenza Vaccine
Maidenhead, UK 14 Dec 2020 Seqirus, a global leader in influenza prevention and influenza pandemic response, today presented new late-breaking data from a systematic review and meta-analysis at...
Dec 11, 2020
11 Dec 2020 The University of Queensland (UQ) and CSL today announce that the Phase 1 trial of the UQ-CSL v451 COVID-19 vaccine has shown that it elicits a robust response towards the virus and...